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Aim: Antimicrobial resistance (AMR) is one of the major health challenges of the future, but the 
concrete impact of counteracting measures is still unclear. To study possible outcomes within the 
European Union, a scenario analysis for the year 2050 was performed on the possible influence of 
the European Commission (EC). 
Methods: Scenario planning and development of strategies based on different scenarios. 
Results: Rational use of antimicrobials in animals and humans, surveillance and monitoring, new 
antimicrobial therapies, travel and globalization, exposure to the environment, and awareness were 
recognized as the main driving elements. Four Scenarios were developed: An efficient and impli-
cated EC sorts out AMR; An implicated but unsuccessful EC withstands AMR; AMR is managed 
regardless of the EC disinterest; and A neutral and inefficient EC fails to manage AMR. 
Conclusion: All the strategies developed on the basis of the four scenarios probe for an increase 
in European Union's dedication to achieve positive outcomes. These include the development of 
effective legislation and international coordination. 
 
Keywords: antimicrobial resistance, European Commission, one health, scenario planning, strate-
gies. 
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Introduction 
Since time immemorial, mankind has strug-
gled with the control of infectious diseases 
which are one of the leading causes of death 
worldwide (1). The COVID-19 pandemic has 
brought infectious diseases as top priority on 
the global health agenda, but in general, most 
of the infections are caused by non-viral 
agents - the bacteria. Luckily, the develop-
ment of antimicrobial agents has remarkably 
helped for treating these infectious diseases: 
antimicrobials can kill or inhibit the growth 
of bacteria by disrupting one or more of their 
essential functions. However, the indiscrimi-
nate and prolific use of antibiotics ensued a 
selection pressure that led to the emergence 
of “antibiotic resistant” organisms, resulting 
in antimicrobial resistance (AMR) (2). It has 
become a major problem given the slow pace 
at which new antibiotics are discovered (3). 
Effective antimicrobial drugs are especially 
needed for preventive and curative measures 
such as ensuring complex procedures (sur-
geries, cancer treatment, transplants) or pro-
tecting patients from fatal diseases (2,4).  
In 2019, AMR has been named as one of the 
top ten threats to global health by the World 
Health Organization (WHO) (5). Apprehen-
sions are rampant that AMR may follow sim-
ilar patterns as seen in case of epidemic out-
breaks developing into pandemics (6). AMR- 
associated burden can be described as its im-
pact on health or on the economy (7). At pre-
sent, AMR is estimated to cause 700,000 
deaths in the world per year and a cumulative 
loss of over 88 trillion Euros by 2050 (2,8). 
Hence, global efforts have been organized to 
face this challenge. The 2015-WHO Global 
Action Plan and 2016-United Nations Politi-
cal declaration on AMR are some of the latest 
undertaken actions worldwide (9). In the Eu-
ropean Union (EU) 25,000 patients die annu-
ally and 1.5 billion euros are expended each 
year due to AMR (8). Consequently, the EU 
reinforced the 2001 Community strategy 
against AMR through the 2011 Commission 
action plan. With its “One Health” approach, 
this action plan addresses AMR in humans 
and animals. Based on previous approaches, 
the European Commission (EC) also devel-
oped guidelines for the prudent use of antimi-
crobials in human health (9). AMR preven-
tion is also a topic for research and educa-
tional projects of the EC, as for example the 
PREVENT IT project (Risk Management and 
Prevention of Antibiotics Resistance) that es-
tablished a collaboration between European 
and Indian universities and NGOs for mutual 
learning (10). To introduce policy interven-
tions, evaluations of AMR burden are per-
formed through morbidity/mortality and eco-
nomic indicators (11).  
Nevertheless, these indicators are the result 
of AMR rather than the factors which cur-
rently influence it. Thus, to ascertain the best 
approaches in the EU, it is imperative to 
acknowledge the factors that will influence 
AMR by 2050. The present paper aims to de-
termine the driving forces of AMR and estab-
lish useful strategies through the develop-
ment of a series of scenarios. These scenarios 
will concern the influence of the EU in com-
bating AMR by the year 2050. 
 
Methods 
Scenario planning is a technique used for an-
ticipating alternative futures. It was origi-
nally founded by economic experts to predict 
large-scale changes. In fact, it is particularly 
convenient in circumstances with high uncer-
tainty. This method is progressively expand-
ing in the public health sector since it takes 
apart the complexity of most public health 
concerns (12). Accordingly, scenario plan-
ning was employed in this study to address 
AMR intricacy and enhancing key strategies 
from the EU perspective. Moreover, this 
method has been applied successfully in the 
context of EU policies earlier as well. For in-
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stance, the White Paper on the Future of Eu-
rope shows five scenarios for how Europe 
could evolve by 2025 (13). 
To execute scenario planning, the process de-
scribed by Neiner et al (12) was followed. 
According to the authors, four steps are 
needed to develop scenario planning in pub-
lic health: (i) Define the sense of purpose; (ii) 
understand driving forces, key patterns and 
trends; (iii) develop scenario plots; and (iv) 
plot strategy, rehearse and converse. Briefly, 
first of all a relevant objective needs to be es-
tablished to define the sense of purpose. In 
this matter, the impact of AMR on public 
health was considered, as it has motivated the 
need for action (14). After all, the EC has rec-
ognized AMR threat and works closely with 
WHO and other partners to accomplish AMR 
global action plan (15). Besides, it aims the 
EU to set best example globally (16). Sec-
ondly, predetermined and unpredictable 
forces shaping the objective need to be deter-
mined. For this purpose, a literature review 
was carried out. As a result, key factors, pre-
vious actions and current involvement of the 
EU in AMR were exposed. Next, alternative 
futures ought to be developed in conformity 
with the forces formerly established. Hereby, 
four scenarios were developed based on 
AMR progress and EC support considering 
the factors ascertained from the literature re-
view. Lastly, valuable strategies should be 
settled irrespective of the scenario contem-
plated. And so, these strategies were ulti-
mately included and argued in the discussion 




Driving forces, key patterns and trends 
The development of resistance basically in-
volves three major determinants: humans, an-
imals, and the environment. Resistant bacte-
ria arising in humans, animals, or the envi-
ronment may spread from one to the other, 
and from one place to another. It spans inap-
propriate antibiotic prescription, uncon-
trolled over-the-counter sale of antibiotics, 
disproportionate use of antibiotics in the food 
for animals (e.g. livestock, aquatic, pets), and 
poor sanitation and hygiene (17). 
Of these, the rational use of antibiotics has a 
major influence on AMR outcomes. Com-
mon infections such as cold, flu are responsi-
ble for the majority of antibiotic prescrip-
tions, however in reality, most of these infec-
tions are caused by viral agents against which 
antibiotics are ineffective (18). The use of an-
tibiotics in these cases is not appropriate, ra-
ther it enhances the risk of AMR. Antibiotics 
also prevail as a prophylactic measure for 
minimizing the consequence of poor farming 
conditions and as a growth accelerator (18). 
To prevent misuse, the EU has published 
guidelines for the prudent use of antimicrobi-
als (19). In this regard, the European Parlia-
ment and the Council of the EU issued the EU 
2019/6 Regulation that prohibits the use of 
antimicrobial as prophylactic agent or growth 
promoter in animals (20). Rational use of an-
tibiotics is a predetermined force since it has 
become a priority for health professionals 
(21).  
Surveillance and monitoring are key ele-
ments of national action plans on AMR (18). 
For instance, at EU level, several agencies are 
involved in AMR surveillance: the European 
Centre for Disease Prevention and Control 
(ECDC), the European Medicines Agency 
(EMA), and the European Food Safety 
Agency (EFSA). Basically, ECDC is respon-
sible for coordinating two surveillance net-
works (EARS-Net and ESAC-Net), while 
EMA and EFSA publish annual reports on 
AMR (18). These are predetermined forces - 
since these agencies are expected to continue 
with their responsibilities. 
Public awareness is another key element in 
combating AMR. The results of Price et al 
(22) substantiated poor understanding of 
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AMR in the general population. As a matter 
of fact, the 2018 Eurobarometer indicated 
57% of Europeans were uninformed that an-
tibiotics are ineffective against viruses (18). 
This unawareness endorses antibiotics’ mis-
use and so AMR. Hence, ECDC established 
the European Antibiotic Awareness Day 
(EAAD) which aims to support the correct 
use of antibiotics through national campaigns 
(16). Though raising AMR awareness per-
haps entail a predictable force, its effective-
ness is certainly unpredictable. 
The discovery of new antimicrobials and di-
agnostic techniques will significantly impact 
AMR (23), therefore more investment is 
needed in basic science (18). For this reason, 
one of the main pillars of One Health Action 
Plan focus on boosting research, develop-
ment and innovation (9). In this regard, the 
EU is developing in coordination with indus-
try for development of new antibacterial 
agents under the COMBACTE-MAGNET 
project (24). Despite the investment, it is un-
predictable when new antimicrobials will be 
ready and if so, what will be their efficacy 
against AMR strains. 
The relevance of the interaction between 
chemicals (antimicrobials, heavy metals, and 
biocides) and pathways (industrial 
wastewater, animal manure) has also been 
emphasized in contributing to the spread of 
AMR. It seems that strict environmental reg-
ulations are needed in the development of 
AMR national action plans (25). The EU 
acknowledges that strong evidence is needed 
to counteract the incomprehension of the en-
vironment role in AMR. To fill this 
knowledge gap, specific actions (such as 
strengthening the role of the Scientific Com-
mittee on Health and Environmental Risks 
(SCHER) on AMR matters) have been in-
cluded in the EU One Health Action Plan (9). 
Despite the EC engagement in the environ-
mental area, the success of this approach is 
yet unpredictable. 
Lastly, travel and globalization have allowed 
newer opportunities for cross-transmission of 
AMR (23). Visitors from developed coun-
tries such as USA often show colonization or 
infections with KPC-, VIM-, OXA-48- and 
especially NDM-producing Enterobacteri-
aceae, upon travel to countries such as 
Greece, Israel, Turkey and Morocco and the 
Indian subcontinent (26). Amongst various 
categories of visits, medical tourism is spe-
cifically linked to the spread of AMR. People 
from developed countries usually undergo 
several types of surgical procedures in devel-
oping countries such as India and China due 
to relatively low treatment costs and shorter 
waiting times for surgeries. Travel and glob-
alization are unpredictable driving forces 




Four scenario plots have been developed, 
based on the anticipated futures resulting 
from AMR progress and EC support. The dif-
ferent scenario plots are presented in Table 1 
and 2. 
The first two scenarios (‘An efficient and im-
plicated EC sorts out AMR’ and ‘An impli-
cated but unsuccessful EC withstands AMR’) 
assumed a strong EC involvement, whereas 
in the last two (AMR is managed regardless 
of the EC disinterest and A neutral and inef-
ficient EC fails to manage AMR) indicates 
that there is no engagement of the EC to en-
counter AMR. Despite the level of support 
provided by the EC, in the first and third sce-
nario (An efficient and implicated EC sorts 
out AMR and AMR is managed regardless of 
the EC disinterest) it is assumed AMR has 
been addressed appropriately. On the con-
trary, the second and fourth scenario (An im-
plicated but unsuccessful EC withstands 
AMR and A neutral and inefficient EC fails 
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AMR 
An implicated but 
unsuccessful EC 
withstands AMR 
AMR is managed 
regardless of the EC 
disinterest 
A neutral and ineffi-


























The EC encouraged 
MS to raise effective 
awareness among the 
population through the 
increase of national 
campaigns. People are 
conscious of the use of 




The EC supported 
MS in developing 
multiple national 
campaigns to raise 
AMR mindfulness. 
Even so, the interven-
tions did not have the 
desired impact and 
the public still use 
antimicrobials indis-
criminately. 
The EC did not en-
courage MS to in-
crease the number of 
national campaigns to 
raise AMR aware-
ness. However, the 
general public is 
more conscious about 
the AMR problem 
and they use antibiot-
ics less indiscrimi-
nately, although mis-
use still exists. 
The EC failed to en-
courage and support 
MS to raise AMR 
awareness through 
sufficient and effective 
national campaigns. 
Citizens misuse antibi-
otics which have in-
creased the number of 
resistant pathogens. 
 An efficient and im-
plicated EC sorts out 
AMR 
An implicated but un-
successful EC with-
stands AMR 
AMR is managed 
regardless of the 
EC disinterest 
A neutral and ineffi-













































the use of antimicrobi-
als. The broad use of 
antimicrobials de-
creased and they are 
uniquely provided 
when indicated in 
guidelines. 
The EC extended the 
guidelines and introduced 
stricter measures for anti-
microbials use. Still, pro-
fessionals do not follow 
the guidelines and 
measures established. 
Antimicrobials are used 
irrationally which has re-
sulted in an increase of 
AMR. 
The EC did not ex-
tend the guidelines 
and measures re-
garding the use of 
antimicrobials. De-
spite this, profes-
sionals are following 
outdated guidelines. 
AMR has slightly 
increased but not as 
much as it was ex-
pected. 
The EC did not ex-
tend the guidelines 
and measures regard-
ing the use of antimi-
crobials. Besides, pro-
fessionals are not fol-





















 Surveillance and eval-
uation of AMR have 
been performed cor-
rectly. Useful infor-
mation has been gath-
ered which allowed to 
develop appropriate 
strategies to confront 
AMR. 
Surveillance and evalua-
tion of AMR have been 
performed correctly and 
more agencies have been 
involved to complete this 
task. Despite the infor-
mation gathered, it has 
not been used appropri-
ately to developed useful 
strategies to approach 
AMR. 
Surveillance and 
evaluation of AMR 




been able to use the 
little information 
gathered to improve 




uation of AMR have 
failed to provide use-
ful information. The 
EC has lost interest in 
monitoring AMR, 
there is no pressure 
from the European 
Parliament or the EC. 
The real status of the 
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The EC has constantly 
been investing in 
AMR research.  The 
investment has pro-
vided good results, 
new antibiotics have 
been discovered and 
new diagnostic tech-
nologies developed. 
AMR exists but there 
are effective resources 
to deal with it. 
The EC has con-
stantly been investing 
in AMR research. 
However, the devel-
opment of new anti-
microbials and diag-
nostics has not im-
proved considerably. 
New advances have 
been made but not 
sufficiently to solve 
the problem. 
The EC decreased the 
investment in re-
search in AMR. The 
development of new 
therapies and diag-
nostics has slowed 
down. Despite this, 
new technologies de-
veloped for other 
health problems have 
been useful to deal 
with AMR and re-
duce its impact. 
The EC stopped the 
investment in research, 
and no new develop-
ment has been 
achieved. Old Antimi-
crobials are still used 
as first and second-line 
treatments. Health pro-
fessionals have to deal 

























The EC has been 
working to involve en-
vironmental regulators 
in AMR national ac-




tion of antimicrobials 
in wastewater is 
strictly controlled and 
treated. No antimicro-
bials are released to 
the environment. 
The EC has been 
working to get envi-
ronmental regulators 
to be more involved 
in AMR national ac-
tion plans. However, 
their coordination 
with stakeholders is 
still insufficient. New 
regulations are con-
sidered to be imple-
mented regarding 
wastewater, but no 
steady action has 
been yet taken. 
The EC did not boost 
the involvement of 
environmental regu-
lators in AMR na-
tional action plans. 
Nonetheless, there is 
coordination between 
environmental regu-
lators and other 
stakeholders. They 
achieved to develop 
strategies to mini-
mize AMR impact in 
the environment.  
The EC did not boost 
the involvement and 
coordination between 
environmental regula-
tors and stakeholders. 
National action plans 
did not include AMR's 
impact on the environ-
ment. Antimicrobials 
are constantly released 
to the environment 
since there is no regu-



















Tourism increased in 
the last years. The EC 
has been working to 
endorse early screen-
ing and control 
measures to tourist ar-
riving from AMR en-
demic areas. These 
measures have been 
successfully applied 
and so, fewer AMR 
pathogens have been 
spread. 
The EC encouraged 
new control measures 
and provided addi-
tional guidance on 
early screening for 
tourists returning 
from AMR endemic 
areas, yet they were 
not strongly fol-
lowed, and several 
AMR strains have 
been locally spread. 
The EC has not con-
sidered the need of 
new guidelines re-
garding early detec-
tion or additional 
measures in tourists. 
Nonetheless, 
healthcare profes-
sionals have been 
able to detect certain 
carriers and limit the 
spread of imported 
AMR strains.  
There EC ignored 
tourism as a AMR 
threat and conse-
quently, no measures 
have been considered 
nor proposed to super-
vise the transit of tour-
ist arriving from AMR 
endemic areas. This 
situation has boosted 
the spread of AMR 





The ongoing COVID-19 pandemic has taught 
us a big lesson that how devastating non-
treatable infectious diseases can be (27). On 
similar league, AMR bears the proficiency of 
attacking us as an epidemic or pandemic. An 
estimate by WHO suggests that approxi-
mately 10 million deaths will happen due to  
 
AMR by 2050. Although just a forecast, 
some of the scenarios described could be as-
sociated with this number of deaths. To de-
crease the odds of these deaths becoming a 
reality, actions must be taken on priority. 
Therefore, the potential influence of driving 
forces has been described in the scenario 
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plots to better understand the ways to combat 
AMR. 
Encouraging legislators to introduce stand-
ards and procedures to assure sensible use of 
antimicrobials will be useful (19). Antibiotics 
could be restricted with a similar approach 
narcotics and psychotropics are controlled 
(regulated by the Single Convention on Nar-
cotic Drugs of 1961 and the Convention on 
Psychotropic Substances of 1971). The de-
velopment of these “Antibiotic Conventions” 
could shift the prescription of antibiotics as a 
first-line treatment to every possible infec-
tion. Nevertheless, to achieve this type of 
covenant a high level of international agree-
ment is required. Stakeholders would clearly 
benefit from this consensus and of these, so-
ciety also plays a fundamental role. Public 
awareness is an influential factor on AMR. 
Thus, further efforts should be considered to 
increase population’s consciousness about 
AMR threat: diversification of AMR cam-
paigns in diverse channels such as TV, radio, 
or social media that could successfully raise 
public awareness.  
In light of newer antibiotics, the development 
of effective antibiotics against resistant 
strains is the need of the hour. A fixed amount 
of money provided by the EC to industry 
could be established as funding to foster new 
antibiotics discoveries. Promoting partner-
ship with industries will also improve the 
likelihood of developing better diagnostics to 
determine the etiologic agents of the diseases 
and, consequently, prescribe antibiotics only 
when necessary. Likewise, the use of artifi-
cial intelligence in AMR surveillance and 
monitoring would allow to analyze existing 
data more precisely and consequently im-
prove outcomes through strategies adapted to 
each circumstance. 
Tourism also represents a relevant threat to 
the spread of AMR strains: tourists may ac-
quire AMR pathogens in their journeys and 
subsequently spread them in their country of 
origin. Early detection of carriers and control 
measures, in combination with international 
cooperation are strategies which could be 
beneficial, if they are successfully applied 
(23,28). On the other hand, it is necessary to 
emphasize the connection between AMR and 
the environment. On this ground, legal 
measures could be established to control 
wastewater treatment, followed by regular in-
spections to assure that legislation is properly 
applied. 
In general, the strategies developed from 
each scenario imply that the outcomes would 
likely be beneficial if there is an increase of 
commitment and coordination between 
stakeholders, especially from the EC. Some 
of the strategies established have been com-
pared with conventions already applied to 
other health challenges, such as the Psycho-
tropic and Narcotic Drug Conventions. 
Nonetheless, to achieve these methods, fur-
ther collaboration and coordination are 
needed not only among Member States but 
also at international level. The EU-India col-
laboration contributing to this global perspec-
tive (10). The global position also empha-
sizes the important role the EU plays in this 
global health challenge and the advantageous 
outcomes that could be achieved if the EU is 
fully involved in slowing down AMR. 
On the other hand, the results have shown 
that the EC could address the driving forces 
of surveillance and monitoring, environmen-
tal AMR, treatment innovation, and tourism 
by introducing new legislation. EU legisla-
tion can have a significant impact, not only 
within the Member States but also outside its 
borders. In fact, the EU is currently endorsing 
AMR measures in third countries through 
different actions, like promoting AMR-re-
lated standards in its bilateral Free Trade 
Agreements (FTAs) (9). These actions under-
pin the role of the EU as a global actor in the 
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AMR challenge and highlights, again, the im-
portance of developing and reinforcing inter-
national collaboration.  
Limitations: The initial inquiry necessary for 
determining the trends and driving forces was 
not based on a systematic literature review. 
Scenario planning is a method based on as-
sumptions and therefore subject to bias, yet 
the non-systematic research of driving forces 
increases the risk of bias. Besides, some of 
the driving forces, though acknowledged, 
were not included in the scenario planning as 
per the scope of this paper. For instance, the 
use of vaccination has shown positive effects 
in reducing AMR, although its success has 
been historically under-recognized so far 
(29). Lastly, the mutual influence between 
driving forces were not considered since 
none of the driving forces would uniquely 
impact AMR but also influence one another. 
Therefore, further scenarios and strategies 
should be developed in the future, including 
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